Session Title: Vitreoretinal Surgery I
Session Date/Time: Thursday 17/09/2015 | 08:30-10:30
Paper Time: 10:14
First Author: : H.Gerding SWITZERLAND
Co Author(s): :
PURPOSE:Recently Acid violet 17 (ala purple®) was approved as a novel dye for intravital staining of the internal limiting membrane. So far no clinical reports are available beyond the level of in vitro- and in vivo-test in cell culture- and animal experiments.
Institutional case series.
Acid violet 17 was used in 53 eyes (53 patients, mean age 72.3+/-8.2 years) during vitreoretinal interventions in order to stain the ILM. Main indications were: epiretinal fibroplasias (n=43), macular hole (n=5), and other diseases (n=4).
Intraoperatively it was obvious that Acid violet 17 is selectively staining the ILM. The intensity score of the staining effect (2.6+/-0.7, maximum score: 5) was significantly better than that of brilliant blue (mean score 2.1+/-1.0, p<0.001). Adverse effects so far observed were: 1. a transient staining of hydrophilic intraocular lenses (12 of 29, 41%) and 2. a severe visual acuity loss in one of five cases with macular hole (preoperative visual acuity 0.2p, postoperatively counting fingers).
Acid violet 17 provides an improved staining effect of the internal limiting membrane in vitreoetinal interventions. Staining of hydrophilic IOL was observed as a new complication of Acid violet 17 use. Clinical safety studies and long-term follow-up data are so far not available.